Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 20,319

Document Document Title
WO/2019/072864A1
The present invention pertains to a process for the preparation of polymorph form X of agomelatine, which comprises providing agomelatine, and crystallizing agomelatine in the presence of at least one of an acid and a salt thereof, and t...  
WO/2019/071348A1
There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying exci...  
WO/2019/074749A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder...  
WO/2019/073471A1
Novel compounds usable in modulating an activity or function of a voltage-dependent potassium channel and/or of TRPV1 are provided. The compounds are represented by Formula I as described and defined in the specification.  
WO/2019/074747A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated dise...  
WO/2019/068912A1
A N-hydrocarbyldiamide composition comprising: a) a compound of formula (Ia), wherein R1 is selected from linear or branched or cyclic, saturated or unsaturated, hydrocarbon chains having from 1 to 40 carbon atoms, R2 is selected from li...  
WO/2019/069697A1
The problem addressed by the present invention is solved by a liquid crystal composition and a liquid crystal display element including the same, the liquid crystal composition containing one or more types of a compound in which a unival...  
WO/2019/063955A1
The present invention concerns the compounds of the following formula (I): (I) in which: - X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, - The X--Y bond and Y are absent if X represents an oxygen or sulfur ...  
WO/2019/067974A1
Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and me...  
WO/2019/051222A1
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...  
WO/2019/046931A1
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...  
WO/2019/047826A1
An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically...  
WO/2019/051184A1
Provided herein are acrylamide and acrylonitrile compounds and other compounds that may be produced from hydroxy amides and/or lactones. Provided herein are methods and systems to produce such compounds.  
WO/2019/044946A1
A method for producing a compound represented by formula (C), the method comprising a step for converting a compound represented by formula (B) (wherein R1 represents an amino group protected by a protecting group) by intramolecular cycl...  
WO/2019/042086A1
The present invention discloses a method and a device for purifying 2-nitro-4-acetamidoanisole and a product purified thereby. The 2-nitro-4-acetamidoanisole is prepared by using p-acetaminoanisole as a raw material to perform mixed acid...  
WO/2019/041596A1
Disclosed are a compound for treating and/or preventing an immune disorder disease and an application thereof. The application provided by the present invention is specifically an application of a compound represented by formula I or for...  
WO/2019/040992A1
The invention relates to oleoyl-lysophosphatidylinositol (oleoyl-LPI) and new synthetic derivatives thereof and uses thereof, and to pharmaceutical compositions comprising such compounds. The invention provides activators and/or up-regul...  
WO/2019/046368A1
The present invention relates to compounds of formula (I) :, including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.  
WO/2019/038764A1
The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.  
WO/2019/040869A1
This invention relates to compounds for treating a protozoan parasitic infection and to pharmaceutical compositions comprising the compounds; and to methods of using the compounds and compositions to treat parasitic infections.  
WO/2019/035453A1
Provided is a catalyst represented by general formula (1). In general formula (1), R1-R14 each independently represent a hydrogen atom or a substituent.  
WO/2019/036678A1
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.  
WO/2019/033219A1
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show util...  
WO/2019/036000A1
Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, L1, L2, G1, G2, G3, a, b, c and d are as d...  
WO/2019/031472A1
[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) o...  
WO/2019/031470A1
[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) o...  
WO/2019/032743A1
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.  
WO/2019/027456A1
The present disclosure generally pertains to novel water soluble oligomeric and polymeric additives derived from oligomeric and polymeric amines; esters or halides of twin tail alkyl group comprising acids with intervening quaternary amm...  
WO/2019/027855A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or d...  
WO/2019/027856A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or ...  
WO/2019/026994A1
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...  
WO/2019/018592A3
The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyra zolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cy clohexyl)acetamide, as well as novel ...  
WO/2019/016269A1
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.  
WO/2019/011279A1
The present disclosure relates to an N-(substituted naphthyl-ethyl) substituted amide compound and uses thereof serving as a melatonin receptor agonist and 5-HT2c receptor antagonist, and specifically relates to the compound of formula (...  
WO/2019/011349A1
Disclosed are an FLZ crystal B form, a preparation method, and a composition and the use thereof, in particular the crystal B form of an FLZ compound (I) (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)- N-(4-h...  
WO/2019/008506A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defi...  
WO/2019/009317A1
Provided are: a novel compound usable as an organic tag which has a high stability under acidic conditions in peptide synthesis, etc.; and a method for highly efficiently producing a peptide wherein the compound is used as an organic tag.  
WO/2019/005841A1
Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial in...  
WO/2018/236913A1
Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used f...  
WO/2018/237344A1
Disclosed herein are methods and compounds for treating a cancer is characterized with an elevated expression of thioredoxin reductase (TrxR) or an elevated expression of peroxiredoxin (PRDX). In some embodiments, also disclosed herein a...  
WO/2018/227620A1
Disclosed is a method for enantioselective synthesis of cis-imidazolines and related structures through chiral resolution. A chiral acid is used to separate enantiomeric precursors of the cis-imidazolines from a racemic mixture by select...  
WO/2018/225093A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (IIIQ): wherein X6', a, b, C8', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82'...  
WO/2018/226169A2
The present invention relates to a new diethanolamine derivative chelating agent having a high water solubility, a good chelating property, and biological degradation. The said new chelating agent can be prepared from reaction of diethan...  
WO/2018/220644A1
The invention provides lipo-polymeric nanoparticles and their preparation. The process involves dissolving polydiacetylene in dimethyl sulfoxide and a phospholipid in chloroform followed by adding 1-Ethyl-3-(3-dimethylaminopropyl) carbod...  
WO/2018/221604A1
The present invention provides a method for industrially producing: a pyrimidine compound having pest control efficacy; 2-[4-(trifluoromethyl)phenyl]ethylamine, which is a production intermediate of the pyrimidine compound; a phenylethyl...  
WO/2018/215070A1
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...  
WO/2018/215610A1
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...  
WO/2018/213140A1
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...  
WO/2018/210274A1
Provided is a novel, mild, highly effective, and economic process for co-producing formamide and monofunctional or polyfunctional acrylamide compounds.  
WO/2018/213082A1
Provided herein are compounds, compositions and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.  

Matches 1 - 50 out of 20,319